Tourmaline Bio (TRML) News Today $24.00 +0.50 (+2.13%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Tourmaline Bio FY2024 EPS Forecast Lowered by HC WainwrightTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - HC Wainwright decreased their FY2024 earnings per share estimates for shares of Tourmaline Bio in a research note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.85) per shareNovember 14, 2024 | marketbeat.comTourmaline Bio to Host Investor Day on Tuesday, December 10, 2024November 14, 2024 | globenewswire.comTourmaline Bio price target raised to $49 from $48 at H.C. WainwrightNovember 12, 2024 | markets.businessinsider.comTourmaline Bio, Inc. Reports Third Quarter Financial ResultsNovember 11, 2024 | tipranks.comTourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC WainwrightHC Wainwright increased their price objective on Tourmaline Bio from $48.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday.November 11, 2024 | marketbeat.comTourmaline Bio’s Promising Clinical Developments and Financial Stability Underpin Buy RatingNovember 11, 2024 | markets.businessinsider.comTourmaline Bio files $350M mixed securities shelfNovember 9, 2024 | markets.businessinsider.comTourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | globenewswire.comAlphaCentric Advisors LLC Sells 69,500 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)AlphaCentric Advisors LLC reduced its position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 92.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,500 shares of the company's stock after selling 69,500 shares during the peNovember 5, 2024 | marketbeat.comTourmaline Bio: Unlocking Value through Promising IL-6 Inhibition Strategy in ASCVD TreatmentNovember 5, 2024 | markets.businessinsider.comTourmaline Bio to Present at Upcoming Investor ConferencesOctober 31, 2024 | globenewswire.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Down 20.0% in OctoberTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 1,520,000 shares, a decrease of 20.0% from the September 30th total of 1,900,000 shares. Currently, 10.2% of the company's stock are short sold. Based on an average daily volume of 202,700 shares, the short-interest ratio is presently 7.5 days.October 27, 2024 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Tourmaline Bio (TRML)October 25, 2024 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Stock Quotes, Forecast and News SummaryOctober 24, 2024 | benzinga.comGet Your First Look at Tourmaline’s Definitive Marsha P. Johnson BiographyOctober 23, 2024 | msn.comPiper Sandler Sticks to Its Buy Rating for Tourmaline Bio (TRML)October 17, 2024 | markets.businessinsider.comTourmaline Bio, Inc. to Post FY2024 Earnings of ($2.85) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TRML)Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research report issued on Tuesday, October 15th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.85)October 17, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading Up 6.3% - Time to Buy?Tourmaline Bio (NASDAQ:TRML) Shares Up 6.3% - Still a Buy?October 16, 2024 | marketbeat.comCantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to Strong-BuyCantor Fitzgerald upgraded shares of Tourmaline Bio to a "strong-buy" rating in a report on Tuesday.October 16, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Gap Up - Here's What HappenedTourmaline Bio (NASDAQ:TRML) Shares Gap Up - Should You Buy?October 15, 2024 | marketbeat.comTourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024October 15, 2024 | globenewswire.comCubist Systematic Strategies LLC Purchases Shares of 37,861 Tourmaline Bio, Inc. (NASDAQ:TRML)Cubist Systematic Strategies LLC purchased a new stake in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 37,861 shares of the company's stock, valued at approximately $487,October 13, 2024 | marketbeat.comTourmaline Bio (TRML) Gets a Buy from Truist FinancialOctober 11, 2024 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Shares Gap Down - Here's WhyTourmaline Bio (NASDAQ:TRML) Shares Gap Down - Here's What HappenedOctober 11, 2024 | marketbeat.comTourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health CongressOctober 11, 2024 | globenewswire.comTourmaline Bio (NASDAQ:TRML) Stock Price Down 4.3% - Should You Sell?Tourmaline Bio (NASDAQ:TRML) Shares Down 4.3% - What's Next?October 9, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading 6.4% Higher - What's Next?Tourmaline Bio (NASDAQ:TRML) Shares Up 6.4% - What's Next?October 8, 2024 | marketbeat.comTourmaline Bio Announces Formation of Cardiovascular Scientific Advisory BoardOctober 8, 2024 | globenewswire.comAlgert Global LLC Has $513,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Algert Global LLC grew its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 122.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,866 shares of the company's stock after puOctober 7, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Acquired by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP boosted its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 18.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,715,401 shares of the company's stockSeptember 28, 2024 | marketbeat.comRhumbline Advisers Increases Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Rhumbline Advisers increased its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 28,554.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,239 shares of the company's stock after purchSeptember 27, 2024 | marketbeat.comHighVista Strategies LLC Acquires 30,345 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)HighVista Strategies LLC increased its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 57.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 83,397 shares of the company's stock after purchasing an additional 30,345 shares during theSeptember 23, 2024 | marketbeat.comBank of New York Mellon Corp Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Bank of New York Mellon Corp bought a new position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 70,697 shares of the company's stock, valued at approximately $909,000.September 22, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Up 3.9%Tourmaline Bio (NASDAQ:TRML) Trading Up 3.9%September 18, 2024 | marketbeat.comTruist Financial Remains a Buy on Tourmaline Bio (TRML)September 11, 2024 | markets.businessinsider.comTRML Sep 2024 35.000 callSeptember 8, 2024 | au.finance.yahoo.comTourmaline Bio (TRML) Receives a Buy from Piper SandlerSeptember 5, 2024 | markets.businessinsider.comTourmaline Bio to Present at Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comTourmaline Bio, Inc. (NASDAQ:TRML) CEO Acquires 5,221 SharesAugust 21, 2024 | insidertrades.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Recommendation of "Buy" from AnalystsTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokeraAugust 21, 2024 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) CEO Sandeep Chidambar Kulkarni Purchases 5,221 SharesTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) CEO Sandeep Chidambar Kulkarni bought 5,221 shares of Tourmaline Bio stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $13.79 per share, for a total transaction of $71,997.59. Following the acquisition, the chief executive officer now directly owns 5,221 shares in the company, valued at approximately $71,997.59. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.August 20, 2024 | marketbeat.comTRML Mar 2025 25.000 callAugust 13, 2024 | ca.finance.yahoo.comBuy Rating Affirmed for Tourmaline Bio Amid Promising Clinical Trials and Strong Market PotentialAugust 13, 2024 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $48.00 price objective on shares of Tourmaline Bio in a research report on Monday.August 12, 2024 | marketbeat.comVanguard Group Inc. Has $20.94 Million Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Vanguard Group Inc. grew its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 19.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 914,519 shares of the company's stock after buying an additional 150,767 shAugust 12, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Issues Quarterly Earnings ResultsTourmaline Bio (NASDAQ:TRML - Get Free Report) posted its earnings results on Thursday. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.04.August 10, 2024 | marketbeat.comTRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024August 8, 2024 | investorplace.comTourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 8, 2024 | globenewswire.comTourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024August 2, 2024 | globenewswire.comTourmaline Bio, Inc. (NASDAQ:TRML) Sees Significant Growth in Short InterestTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 2,090,000 shares, an increase of 36.6% from the June 30th total of 1,530,000 shares. Based on an average daily volume of 356,100 shares, the short-interest ratio is currently 5.9 days. Approximately 13.6% of the company's stock are sold short.July 27, 2024 | marketbeat.com Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! TRML Media Mentions By Week TRML Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRML News Sentiment▼0.100.45▲Average Medical News Sentiment TRML News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRML Articles This Week▼52▲TRML Articles Average Week Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Longboard Pharmaceuticals News Arrowhead Pharmaceuticals News Protagonist Therapeutics News IDEAYA Biosciences News CG Oncology News Keros Therapeutics News Wave Life Sciences News Akero Therapeutics News Amphastar Pharmaceuticals News Apogee Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRML) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
